$21.4291
0.1681[0.79%]
At close: Apr 26
Latest News for Harbor ETF Trust Harbor Multi-Asset Explorer ETF (ARCA:MAPP)
Harbor ETF Trust Harbor Multi-Asset Explorer ETF (ARCA: MAPP)
Categories: All
Friday, March 01, 2013
- UPDATE: Wedbush Downgrades MAP Pharmaceuticals to Neutral, Reiterates $25 PT on Likely AcquisitionBenzinga - Mar 1, 2013, 2:08PM
- Wedbush Downgrades MAP Pharmaceuticals, Inc. to Neutral, Maintains $25.00 PTBenzinga - Mar 1, 2013, 12:55PM
- Allergan Announces Intent to Exercise Top-Up Option, Expiration of Offer of MAP Pharma Shares, Says 30.5M Shares Validly Tendered, Not Properly WithdrawnBenzinga - Mar 1, 2013, 9:02AM
Friday, February 15, 2013
Thursday, February 07, 2013
Friday, February 01, 2013
Wednesday, January 30, 2013
Monday, January 28, 2013
Thursday, January 24, 2013
Wednesday, January 23, 2013
- Benzinga's M&A Chatter for Wednesday January 23, 2013Benzinga - Jan 23, 2013, 6:43PM
- Leerink Swann Downgrades MAP Pharmaceuticals, Inc. to Market PerformBenzinga - Jan 23, 2013, 5:58PM
- Mid-Day Market Update: AMD Remains Up, Cyberonics Takes a BeatingBenzinga - Jan 23, 2013, 12:52PM
- MAP Skyrockets Off the Map on Allergan AcquisitionBenzinga - Jan 23, 2013, 12:23PM
- Mid-Morning Market Update: Cree Continues Earnings Fueled Rally, General Dynamics Feels Defense Spending SlowdownBenzinga - Jan 23, 2013, 10:37AM
Tuesday, January 22, 2013
Friday, November 23, 2012
Wednesday, August 01, 2012
Tuesday, July 31, 2012
Friday, July 13, 2012
Thursday, July 12, 2012
Monday, June 25, 2012
Monday, May 07, 2012
Friday, May 04, 2012
Thursday, April 12, 2012
Friday, March 30, 2012
Thursday, March 29, 2012
Wednesday, March 28, 2012
Tuesday, March 27, 2012
- Wedbush Securities Maintains MAP Pharmaceuticals at Outperform, Lowers PT from $30 to $25Benzinga - Mar 27, 2012, 12:07PM
- MAP Pharmaceuticals Trading 0.8% Lower on Heavy Volume; Currently at $17.01Benzinga - Mar 27, 2012, 11:26AM
- Morning Social Media Outlook for Tuesday March 27 (ISTA, LNDC, CALM, MAPP)Benzinga - Mar 27, 2012, 10:19AM
- MAP Pharmaceuticals Trading 10.7% Lower on Heavy Volume; Currently at $15.31Benzinga - Mar 27, 2012, 10:02AM
- UPDATE: Map Says It Will Provide Updates on Further FDA Clarity; Working to Put Redundant Supplier in Place; Possible FDA Will Turn Down Meeting RequestBenzinga - Mar 27, 2012, 8:56AM
- UPDATE: MAP Says FDA Didn't Mention Concerns of Phase III Study DesignBenzinga - Mar 27, 2012, 8:39AM
- UPDATE: MAP Pharma Will Request FDA Meeting Today; Believes It Has Strong Support from Allergan; FDA May Take 60-75 Days to Have Meeting; DA Issue Has No Effect on Allergan ContractBenzinga - Mar 27, 2012, 8:28AM
- MAP CEO Says Approval Milestone with Allergan $50MBenzinga - Mar 27, 2012, 8:25AM
- MAP Pharma Falls as Much as 35% on CRLBenzinga - Mar 27, 2012, 8:20AM
- UPDATE: MAP CEO Says FDA Wanted More Time to Review Data; Doesn't See Any Need for Changes to the DeviceBenzinga - Mar 27, 2012, 8:13AM
- UPDATE: MAP CEO Says FDA Had Questions on Inhaler UsabilityBenzinga - Mar 27, 2012, 8:11AM
- MAP CEO Says Third-Party Manufacturer was FDA ConcernBenzinga - Mar 27, 2012, 8:10AM
- Benzinga's Top Pre-Market LosersBenzinga - Mar 27, 2012, 8:09AM
- MAP Pharma Says FDA Didn't Require More Clinical StudyBenzinga - Mar 27, 2012, 8:08AM
- JP Morgan on MAP Pharmaceuticals Delayed Approval of LevadexBenzinga - Mar 27, 2012, 7:49AM